LARYNGEAL PAPILLOMATOSIS
Abstract
Background. Laryngeal papillomatosis is a rare disease of the upper respiratory tract, which may have a dramatic course. The results of many studies have proved a viral etiology, but the precise mode of the virus transmission remains indistinct. Surgery is the most successful mode of treatment. Adjuvant therapy is indicated only in an aggressive form of the disease.
Patients. In the last 23 years, 136 patients have been treated for laryngeal papillomatosis at the Department of Otorhinolaryngology and Cervicofacial Surgery in Ljubljana. All patients were treated surgically; since 1995, CO2 laser has been used. Eighteen patients with aggressive disease received adjuvant therapy. Only in 2.2% of patients was tracheotomy necessary. In 9.6% of patients, laryngeal scarring occurred as a result of repeated surgical procedures. In 2.2%, malignant alteration of laryngeal papillomatosis developed.
Conclusions. The outcome of treatment of laryngeal papillomatosis in Ljubljana is comparable to the results of other centres. As carcinoma may develop, although very rarely, more than 10 years after the onset of laryngeal papillomatosis, all patients must be followed carefully.
Downloads
References
Morgan AH, Zitsch RP. Recurrent respiratory papillomatosis in children: a retrospective study of management and complications. Ear Nose Throat J 1986; 65: 19–28.
Gissman L, Wolnick L, Ikenberg H. Human papillomavirus type 6 and 11 DNA sequence in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci USA 1983; 80: 560–3.
Gale N, Poljak M, Kambič V, Ferluga D, Fischinger J. Laryngeal papillomatosis: molecular, histopathological, and clinical evaluation. Virchows Archiv 1994; 425: 291–5.
Doyle DJ, Henderson LA, LeJeune FE, Miller RH. Changes in human papillomavirus typing of recurrent respiratory papillomatosis progressing to malignant neoplasm. Arch Otolaryngol Head Neck Surg 1994; 120: 1273–6.
Lin K-Y, Westra WH, Kashima HK, Mounts P, Wu T-C. Coinfection of HPV-11 and HPV-16 in a case of laryngeal squamous papillomas with severe dysplasia. Laryngoscope 1997; 107: 942–7.
Derkay CS, Darrow DH. Recurrent respiratory papillomatosis of the larynx: current diagnosis and treatment. Otolaryngol Clin North Am 2000; 33: 1127– 42.
Green GE, Bauman NM, Smith RJ. Pathogenesis and treatment of juvenile onset recurrent respiratory papillomatosis. Otolaryngol Clin North Am 2000; 33: 187–207.
Bennett RS, PowellKR. Human papillomaviruses: association between laryngeal papillomas and genital warts. Pediatr Infect Dis 1987; 6: 229–32.
Kashima HK, Shah F, Lyles A et al. A comparison of risk factors in juvenileonset and adult-onset recurrent respiratory papillomatosis. Laryngoscope 1992; 109: 9–13.
Vambutas A, Bonagura VR, Steinberg BM. Altered expression of TAP-1 and major histocompatibility complex class I in laryngeal papillomatosis: correlation of TAP-1 with disease. Clin Diagn Lab Immunol 2000; 7: 79–85.
Snowden RT, Thompson J, Horwitz E, Stocks RM. The predictive value of serum interleukins in recurrent respiratory papillomatosis: a preliminary study. Laryngoscope 2001; 111: 404–8.
Derkay CS. Task force on recurrent respiratory papillomas. Arch Otolaryngol Head Neck Surg 1995; 121: 1386–91.
Lindeberg H, Elbrond O. Laryngeal papillomas: the epidemiology in a Danish subpopulation 1965–1984. Clin Otolaryngol 1990; 15: 125–31.
Lindeberg H, Oster S, Oxlund I, Elbrond O. Laryngeal papillomatosis: classification and course. Clin Otolaryngol 1986; 11: 423–9.
Doyle DJ, Gianoli GJ, Espinola T, Miller RH. Recurrent respiratory papillomatosis: juvenile versus adult forms. Laryngoscope 104: 523–7.
Bauman NM, Smith RJ. Recurrent respiratory papillomatosis. Pediatr Clin North Am 1996; 43: 1385–401.
Hartley C, Hamilton J, Birzgalis AR, Farrington WT. Recurrent respiratory papillomatosis – the Manchester experience, 1974–1992. J Otol Laryngol 1994; 108: 226–9.
Rimell FL, Schoemaker DL, Pou AM, Jordan JA, Post JC, Ehrlich GD. Pediatric respiratory papillomatosis: prognostic role of viral typing and cofactors. Laryngoscope 1997; 107: 915–8.
Bergler WF, Götte K. Current advances in the basic research and clinical management of juvenile-onset recurrent respiratory papillomatosis. Eur Arch Otolaryngol 2000; 257: 263–9.
Derkay CS. Recurrent respiratory papillomatosis. Laryngoscope 2001; 111: 57–69.
Kashima HK, Mounts P, Leventhal B, Hruban RH. Sites of predilection in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 1993; 102: 580–3.
Kambič V, Gale N. Epithelial hyperplastic lesions of the larynx. Amsterdam: Elsevier 1995; 181–95.
Michaels L, Hellquist HB. Ear, nose and throat histopathology. London: Springer , 2001: 369–77.
Armstrong LR, Derkay CS, Reeves WC. Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch Otolaryngol Head Neck Surg 1999; 125: 743–8.
Cole RR, Myer CM, Cotton RT. Tracheotomy in children with recurrent respiratory papillomatosis. Head Neck 1989; 11: 226–30.
Mahnke CG, Werner JA, Frölich O, Lippert BM, Hoffman M, Rudert HH. Klinische und molekularbiologische Untersuchungen zur laryngalen Papillomatose. Laryngo Rhino Otol 1998; 77: 27–33.
Benjamin B, Parsons DS. Recurrent respiratory papillomatosis: a 10 year study. J Laryngol Otol 1988; 102. 1022–8.
Chipps BE, McClurg FL Jr, Freidman EM, Adams GL. Respiratory papillomatosis: presentation before six months. Pediatr Pulmonol 1990; 9: 125–30.
Pou AM, Rimell FL, Jordan JA et al. Adult respiratory papillomatosis: human papillomavirus type and viral coinfections as predictors of prognosis. Ann Otol Rhinol Laryngol 1995; 104: 758–62.
Klozar J, Taudy M, Betka J, Kana R. Laryngeal papilloma – precancerous condition? Acta Otolaryngol (Stockh) 1997; Suppl 527: 100–2.
Dedo HH, Yu KC. CO2 laser treatment in 244 patients with respiratory papillomas. Laryngoscope 2001; 111: 1639–44.
Crockett DM, McCabe BF, Shive CJ. Complications of laser surgery for recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 1987; 96: 639–44.
Perkins JA, Inglis AF Jr, Richardson MA. Iatrogenic airway stenosis with recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 1998; 124: 281–7.
Zeitels SM, Sataloff RT. Phono-microsurgical resection of glottal papillomatosis. J Voice 1999; 13: 123–7.
McMillian K, Shapsay SM, McGillian JA, Wang Z, Rebeiz EE. A 585-nanometer pulsed dye laser treatment of laryngeal papillomas: preliminary report. Laryngoscope 1998; 108: 968–72.
Bergler W, Hönig M, Götte K, Petroianu G, Hormann K. Treatment of recurrent respiratory papillomatosis with argon plasma coagulation. J Laryngol Otol 1997; 111: 381.4.
Parsons DS, Bothwell MR. Powered instrument papilloma excision: an alternative to laser therapy for recurrent respiratory papilloma. Laryngoscope 2001; 111: 1494–6.
Myer CM III, Wilging P, Mc Murray S, Cotton RT. Use of a laryngeal micro resector system. Laryngoscope 1999; 109: 1165–6.
Kashima HK, Leventhal BG, Dedo HH, et al. Interferon alpha-N1 (Wellferon) in juvenile onset recurrent respiratory papillomatosis: results of a randomized study in twelve collaborative institutions. Laryngoscope 1988; 98: 334– 40.
Leventhal BG, Kashima HK, Mounts P, et al. Long-term response of recurrent respiratory papillomatosis to treatment with lymphoblastoid interferon alfa-n1. N Eng J Med 1991; 325: 613–7.
Healy GB, Gelber RD, Trowbridge Al, et al. Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. N Eng J Med 1988; 319: 401–6.
Walther EK, Herberhold C. Behandlung der laryngotrachealen Papillomatose mit kombinierter Anwendung von Laserchirurgie und intraläsionaler Applikation von Alpha-Interferon (Roferon). Laryngo-Rhino-Otol 1993; 72: 485–91.
Endres DR, Bauman NM, Burke D, Smith RJH. Acyclovir in the treatment of recurrent respiratory papillomatosis. A pilot study. Ann Otol Rhinol Laryngol 1994; 103: 301–5.
Kiroglu M, Cetik F, Soylu L, et al. Acyclovir in the treatment of recurrent respiratory papillomatosis: a preliminary report. Am J Otolaryngol 1994; 15: 212–4.
Mc Glennen RC, Adams GL, Lewis CM, Faras AJ, Ostrow RS. Pilot trial of ribavirin for the treatment of laryngeal papillomatosis. Head Neck 1993; 15: 504–12.
Snoeck R, Wellens W, Desloovere C, Van Ranst M, Naesens L, De Clerq E, Feenstra L. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir (S)-1(3-hydroxy-2-phosphonylmethoxypropyl) citosine. J Med Virol 1998; 54: 219–25.
Pransky SM, Brewster DF, Magit AE, Kearns DB. Clinical update on 10 children treated with intralesional cidofovir injections for severe recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2000; 126: 1239–43.
Newfield L, Goldsmith A, Bradlow HL, Auborn K. Estrogen metabolism and human papillomavirus-induced tumors of the larynx: chemo-prophylaxix with indole-3carbinol. Anticancer Res 1993; 13: 337–42.
Rosen CA,Woodson GE, Thompson JW, Hengesteg AP, Bradlow HL. Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 1998; 118: 810–5.
Eicher SA, Taylor-Cooley LD, Donovan DT. Isotretinoin therapy for recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 1994; 120: 405–9.
Bell R, Hong WK, Itri LM, et al. The use of cis-retinoic acid in recurrent respiratory papillomatosis of the larynx: a randomized pilot study. Am J Otolaryngol 1988; 9: 161–7.
Shikowitz MJ, Abramson AL,Freeman K, Steinberg BM, Nouri M. Efficacy of DHE photodynamic therapy for respiratory papillomatosis: immediate and long-term results. Laryngoscope 1998; 108: 962–7.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
